NICE green lights two blood cancer therapies for NHS use
BMS’ Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.
Cancer
World Cancer Day: WHO warns of rising cancer burden in Southeast Asia
People-focused cancer care demands policy support
FDA expands Enhertu approval to include HER2-ultralow breast cancer patients
AstraZeneca gains NICE nod for lung cancer drugs Tagrisso and Imfinzi
J&J’s Lazcluze/Rybrevant combination obtains European approval to treat NSCLC
BeiGene’s Tevimbra approved in US for first-line gastric cancer treatment
BeiGene’s PD-1 drug approved in EU for first-line oesophageal cancer treatment
